Home generic drugs

Keyword: generic drugs

52 results found

In 2023, diabetes medications remained the leading drug category for eligible private insurance claims for the second consecutive year, according to Telus Health’s annual drug trends report. The report, based on claims data from more than 15 million plan members in 2023, found the growing prevalence of diabetes, along with expanded heart failure treatment indications and […]

  • By: Staff
  • April 24, 2024 April 23, 2024
  • 09:00

The union representing 120 employees working across Canada for U.S. telecommunications company Zayo Group has ratified a four-year collective agreement that includes pension and benefits gains. Unifor Local 2000A was able to protect and maintain the company’s defined benefit pension plan; however, the employee contribution will increase from three per cent to 4.5 per cent. […]

  • By: Staff
  • April 2, 2024 April 2, 2024
  • 09:00
Copyright_jenifoto_123RF

Changes to the Public Service Health Care Plan, which took effect on July 1, include $75,000 for certain gender affirming procedures not covered by provincial or territorial health-care programs. Other new benefits include: $300 per year each for a registered dietician, occupational therapist and lactation consultant; $200 per year for batteries for hearing aids; $600 per […]

  • By: Staff
  • July 27, 2023 July 26, 2023
  • 09:00

With the cost of drug claims continuing to rise in 2021, benefits plan sponsors can enable certain drug programs to curb costs, keeping their plans sustainable and offering the benefits that members highly value, said Lavina Viegas, director of pharmacy operations at Telus Health, during a session at Benefits Canada’s 2022 Face to Face Drug […]

The increasing use of high-cost medicines is the primary cost driver for all Canadian drug plans, according to a new report by the Patented Medicine Prices Review Board. It found drug costs for public plans rose by 5.3 per cent in 2019/20, with high-cost medicines accounting for 6.3 per cent of the increase. Among private […]

  • By: Staff
  • November 25, 2022 November 24, 2022
  • 09:00
Copyright_truthfunctional_123RF

The union representing 225 part-time workers at Metro Inc. warehouses in Etobicoke, Ont. has ratified a three-year agreement that includes multiple benefits gains. Unifor members voted overwhelmingly in favour of a collective agreement that includes a prescription drug plan for all eligible part-time workers. The plan offers single coverage with a three-year maximum of $6,000, […]

Prescription drug costs for public drug plans rose to $12.5 billion in 2019/20, a 3.7 per cent rise in spending since 2017/18, driven primarily by increases in the use of higher-cost drugs, according to a report by the Patented Medicine Prices Review Board. The report, which reviewed data from the National Prescription Drug Utilization Information […]

  • By: Staff
  • November 12, 2021 November 12, 2021
  • 09:00

The first strike at Vale Canada in more than a decade is drawing to a close after unionized workers at the Sudbury, Ont., mine ratified a collective agreement that includes improved pension and health benefits. Through the agreement — which expires May 31, 2026 — the monthly pre-age 65 defined benefit pension will increase by $50 to […]

How plan sponsors can contain rising drug costs in 2021

With drug costs for plan sponsors steadily rising in recent years, keeping budgets down is top of mind as they plan for 2021. “The biggest concern for plan sponsors is sustainability,” said Shawn O’Brien, principal of data enablement and drug, health, dental product roadmap for Telus Health, in a press release. “They have to find a […]

  • By: Staff
  • December 18, 2020 April 23, 2021
  • 09:03
A legislative update on provincial biosimilar policies

When the City of Toronto switched benefits plan insurers in 2017, it changed its coverage for biologics and biosimilars. Under its previous plan, the City reimbursed employees for the drugs their doctors recommended and prescribed; now, it follows its new insurer’s mandatory biosimilars policy, while grandfathering any plan member who was already taking a biologic […]